StemCyte Board of Directors
Our Board of Directors have a strong background in raising funds for large capital ventures. They play an important role in our success here at StemCyte.
Kenneth J. Giacin, MBA, MS
Chairman of the Board of Directors
Ken Giacin joined StemCyte in 2003, bringing world-class leadership to guide the company's growth through new investments and technological affiliations. In addition to being the Chairman of StemCyte, Inc. he also holds the Chairmanship of StemCyte Taiwan and the StemCyte India Joint Venture. Prior to joining StemCyte, Ken had an outstanding and diverse career with Johnson & Johnson that spanned almost 26 years. His last assignment was Senior Vice President of Independence Technology, L.L.C., a Johnson & Johnson Company, which he started, that is dedicated to providing innovative products to people with disabilities and was responsible for all aspects of managing new business opportunities worldwide, a key element in building a global franchise within Johnson & Johnson. He held this position from 2000 to his 2003. From 1995 to 2000 he was General Manager of Independence Technology and served as a member of the Global Management Board throughout.
Ken served Johnson & Johnson in a series of assignments from 1974 to 1991. Beginning in Engineering and Operations with the Domestic Operating Company, he progressed through responsibilities in Operations, Marketing and Business Development and served on the Management Boards of the Baby Products Company as well as Consumer Products, Inc. as Vice President, Business Development.
From 1991 until his return to J&J in 1995, Ken was a Corporate Officer and Vice President, Worldwide Business Development for the Church & Dwight Company reporting to the Chairman. He was responsible for developing brand value and business for the Arm & Hammer Brand on a worldwide basis. In 1994, he added research and development responsibilities as Vice President, Business Development and Technology.
Prior to joining Johnson & Johnson, Ken served with the United States Navy as a carrier pilot and remained actively involved in aviation and non aviation command assignments with the Naval Reserve until his retirement in 1999 with the rank of Captain. He holds a Bachelors of Science, Masters of Science and an MBA, all from Rutgers University.
Ken has also served on a number of Boards and Advisory Panels including
-Board member of Cerebral Palsy of New Jersey
-Advisory Board of the Human Engineering Research Laboratory of the University of Pittsburgh.
-Industrial Advisory Committee to Rutgers University
- Advisory Board of the National Institute for Child Health and Development (NIH)
- Advisory Board of the Pan Pacific Symposium for Stem Cell Research
John Whitman is President of Sycamore Management Corporation (“SMC”), which he helped found in 1995.· Over its life, SMC has raised and managed more than $600.0 million in eight Venture and Private Equity Funds.· The Firm currently has investment operations in the US, China and India.· From 1990 until he joined SMC, Mr. Whitman was an advisor to the Ford Motor Company, AT&T Venture Corp., the Hungarian-American Enterprise Fund, British and Commonwealth Holdings PLC, Coopers & Lybrand, the United States Agency for International Development (U.S.A.I.D.), and Prudential Securities Inc.· From 1987 through 1990, Mr. Whitman was Chairman and Chief Executive Officer of Prudential-Bache Interfunding Inc. (“PBIF”), a US $800 million Merchant Banking Fund entirely financed by the Prudential Insurance Company of America.· During this period, PBIF financed and closed fourteen major leveraged transactions with a total cost basis of US $1.34 billion in equity and bridge loans. To date PBIF has realized US $1.65 billion on these investments.· From 1980 to 1987, while he was a Vice President of Citicorp Venture Capital, Ltd., he completed 11 leveraged transactions with an aggregate cost basis of US $31 million and realized US $141.3 million on them.· From 1972 to 1980, Mr. Whitman held various positions at Citicorp, most notably as Vice President in charge of the Corporate Finance Department of Citicorp International Bank Ltd. in London, and as a principal of Citicorp's corporate distressed loan department.· Mr. Whitman graduated from Yale University in 1966 and received his MBA from the Harvard Business School in 1971.
George J. Lee, Ph.D.
George J. Lee is a general partner and co-founder of AmKey Ventures, LLC, a venture management company specializing in investments in the biotech and pharmaceutical fields.· He has extensive experience in the pharmaceutical industry, having worked in a major pharmaceutical company (Syntex) for 13 years and early stage biomedical companies (Sonus and Shaman Pharmaceuticals) for 7 years. He is an internationally known pioneer in the field of steroid hormones research. His HPLC-RIA method has been recognized as the most accurate and sensitive method for the determination of trace amounts of steroid hormones in the complex biological matrices. He has in depth experience in analytical methods development and validation for New Drug Application (NDA) as well as various applications to the Food & Drug Administration. He is a co-founder of PHARMout Laboratories, Inc., which is a contract research organization specializing in analytical research. PHARMout Laboratories has received excellent results from several FDA inspections. PHARMout Labs has achieved an over 30% net profit margin and consequently provided good return to its shareholders. He earned his Ph.D. degree in chemistry from the State University of New York at Buffalo and a B.S. degree in agricultural chemistry from National Taiwan University, Taiwan.
Greg Bonfiglio is the board representative for NTEC. Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC – an investment and advisory firm focused solely on regenerative medicine. Proteus provides fund management, consulting, and investment banking services to the regenerative medicine industry. Proteus works with clients across all stages of development from early stage to Pharma. Mr. Bonfiglio was an early investor and active participant in the field of stems cell & regenerative medicine, and he continues to be a leader in the field. He is a frequent speaker at Regenerative Medicine Conferences. Mr. Bonfiglio is a Member of the ISSCR and is on their Advisory Board, and Finance Committee. He also is a Member of the ISCT and is on their Commercialization Committee. Mr. Bonfiglio is on the Boards of VistaGen Therapeutics (in vitro tools from hESCs); and California Stem Cell, Inc. (reagents & CNS therapeutics from hESCs). He is the Chairman of the Board of the Centre for Commercialization of Regenerative Medicine (CCRM; RM Translation Center in Toronto, Canada).
Mr. Bonfiglio has over 25 years experience working with technology companies. From 2000 – 2005, Mr. Bonfiglio was a General Partner with Anthem Venture Partners, an early stage venture fund in California. While at Anthem, Mr. Bonfiglio led investments in both biotechnology and IT. Prior to joining Anthem, he was a Partner with Morrison & Foerster, where he worked extensively with technology clients. Mr. Bonfiglio was an Adjunct Professor of Law at Stanford Law School, from 1996 to 2000. Since 1995, he has been a regular Guest Lecturer at the UC Berkley Haas Business School, in the Top Down Law program. Mr. Bonfiglio received his B.A. in Mathematics (magna cum laude) from Michigan State University in 1975, and his J.D. (magna cum laude) from the University of Michigan Law School in 1981.
James C. Lu
Jimmy Lu is the Executive Managing Director and Chief Operating Officer of the WI Harper Group, a venture firm managing $750M in committed capital. From offices in Beijing, Taipei and San Francisco, WI Harper seeks to invest in leading technology companies in the TMT, Cleantech and Healthcare sectors in Greater China and the U.S. Jimmy oversees WI Harper’s global operations and brings to the firm over 20 years of high technology and venture capital experience. He currently serves on the boards of StemCyte Inc., Quixey, Inc., CNano Technology Limited, China Diagnostics Medical Corporation and Kindstar Global Co.
Prior to joining WI Harper, Jimmy co-founded and was a General Partner of iD Ventures America (formerly Acer Technology Ventures), which manages numerous funds, including Acer Technology Venture Fund and IP Fund One. The funds were early investors in iRobot Corporation (NASDAQ: IRBT), Harmonix Music, Monolithic Power Systems (NASDAQ: MPWR) and Fortinet (NASDAQ: FTNT).
Jimmy joined the Acer Group, a leading worldwide technology company, in 1992, and as General Counsel worked closely with senior management to negotiate and structure the Acer Group’s international joint ventures, strategic alliances, acquisitions, global financings and commercial transactions. He assisted in establishing Acer’s first international venture capital fund, Fund 21 Limited. Before joining Acer, Jimmy was with Bingham McCutchen in San Francisco, specializing in M&A and venture transactions, debt and equity financings and public securities work. He also spent several years as a banker with JP Morgan in New York City covering Fortune 500 clients in the Pacific Northwest.
Jimmy has been a panelist or speaker at many conferences sponsored by international business and legal organizations and has also guest lectured and presented at Yale, Harvard, Stanford and Wharton.
Jimmy earned a B.A. from Yale College, an M.B.A. from Harvard Business School and a J.D. from UC Berkeley School of Law (Boalt Hall). He is the Vice-Chair of the Association of Yale Alumni and an Associate Fellow of Trumbull College. He is also a member of the University of Florida College of Engineering’s West Coast Advisory Board.
MeiAnn Liu, Ph.D.
Vice President of Fubon Financial Holding Venture Capital Corporation（FFHVC）
MeiAnn Liu is the Vice President of Fubon Financial Holding Venture Capital Corporation（FFHVC）, which is a fully-owned subsidiary of Fubon Financial Holding Company. Aspiring to become one of Asia’s first-class financial institutions, Fubon Financial offers the most complete and diversified line of financial products and services through its many subsidiaries. It has been the most profitable financial holding company in Taiwan since 2009. FFHVC invests in leading companies in Biotechnology, Healthcare, Energy, Digital content, Service, Infrastructure and Environmental sectors in Taiwan, China and U.S. Dr. Liu oversees the biotech/healthcare investments for Fubon with 12 years of VC experience. She currently serves on the boards of several VC funds and biotech companies.
Prior to joining Fubon, Dr. Liu held varies positions up to Executive Vice President at President Life Sciences Co. and President Biosystems Co. Dr. Liu earned a B.S. from National Taiwan University, a M.S. from University of Massachusetts at Amherst and a Ph.D. in Molecular & Cellular Biology from Harvard University.